[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peritoneal-dialysis-pd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peritoneal-dialysis-pd":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,78,117,145,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100565470","starting-incremental-prescription-of-peritoneal-dialysis-100565470",false,"NCT06642597","STarting incrEmental Prescription of Peritoneal Dialysis","An International, Multi-centre, Randomised Controlled Trial Co-designed With Consumers With Lived Experience of Peritoneal Dialysis (PD) to Determine the Optimal Approach to Starting Patients With Kidney Failure on PD","STEP-PD","Inclusion Criteria:\n\n* adults (≥18 years) commencing PD as their first dialysis therapy (and been on dialysis for \\\u003C1 month)\n* able to give informed consent\n\nExclusion Criteria:\n\n* urine output \\\u003C0.5L\u002Fday\n* previous kidney transplant\n* unlikely to be on dialysis for ≥1 year.\n* known or planned pregnancy during the trial","ALL","18 Years",{"count":20,"type":21},224,"ESTIMATED","INTERVENTIONAL",[24],"NA","Kidney failure is fatal without dialysis. Peritoneal dialysis (PD) completed at home offers greater flexibility and autonomy for patients . However, PD is often prescribed for 24 hours\u002Fday, 7 days\u002Fweek for every patient starting dialysis. This practice is not evidence-informed, may be unnecessary and potentially harmful. The STEP-PD trial aims to determine the optimal approach to commencing patients on PD through starting at low dose PD and incrementing over time.",[27,28],"Peritoneal Dialysis (PD)","Kidney Failure",[30,31,32,33],"Kidney failure","Kidney disease","peritoneal dialysis","incremental start PD","RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":38},"2025-09-19",{"date":42,"type":21},"2029-09-30",{"name":44,"class":45},"The University of Queensland","OTHER",9,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100597551","sensor-based-congestion-alert-for-events-in-peritoneal-dialysis-scale-pd-100597551","NCT07059962","Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)","Sensor-based Congestion Alert for Events in Peritoneal Dialysis (SCALE-PD)","SCALE-PD","Inclusion Criteria:\n\n1. Age 21 years or older\n2. Able to speak and read English, or able to speak and read Spanish and has a caregiver or family member who speaks English and can provide assistance\n3. Able to stand on two bare feet unassisted\n4. Receiving automated peritoneal dialysis for the treatment of ESKD\n5. Followed on the Vantive Sharesource Remote Patient Management Platform\n\nExclusion Criteria:\n\n1. Undergoing or plan to undergo hemodialysis in the next 12 months\n2. Have a life expectancy of less than 12 months\n3. Are pregnant or plan to become pregnant during the next 12 months\n4. Weigh greater than 375 lbs\n5. Planned kidney transplant within the next 12 months\n6. Have an implanted neurostimulator system","21 Years",{"count":57,"type":21},125,"OBSERVATIONAL","To explore the use of the Bodyport Cardiac Scale in predicting worsening of events due to fluid overload in patients with kidney disease on peritoneal dialysis.",[61,27,62],"Kidney Disease","End Stage Kidney Disease (ESRD)",[64,32,65,66],"kidney disease","fluid overload","heart failure","2026-03-17",{"date":69,"type":38},"2026-03-18",{"date":71,"type":38},"2025-09-09",{"date":73,"type":21},"2026-06",{"name":75,"class":76},"Bodyport Inc.","INDUSTRY",4,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100605044","effect-of-a-plant-focused-diet-on-nutritional-status-in-malnourished-peritoneal-dialysis-patients-100605044","NCT07157397","Effect of a Plant-Focused Diet on Nutritional Status in Malnourished Peritoneal Dialysis Patients","Effect of Plant-Focused Diet on Nutritional Status of Malnourished Patients Undergoing Peritoneal Dialysis in a Selected Hospital Care Setting","Inclusion Criteria:\n\n* Adult outpatients (\\>18 years old), attending HTCM PD clinic visits\n* Have undergone peritoneal dialysis for at least 6 months\n* Have a serum albumin level \\\u003C40 g\u002FL\n* Have a BMI of \\\u003C 25 kg\u002Fm2\n* Have a malnutrition inflammation score (MIS) of mild, moderate or severe\n* Agreed to follow the dietary instructions based on the randomization assignment\n* Agreed to attend baseline visits and additional follow-up appointments at months 1, 3, and 6 post- randomization, either in person or via telehealth, and respond to monthly or more frequent phone calls\n\nExclusion Criteria:\n\n* Have been hospitalized for the past 3 months\n* Have ongoing infection\u002Fsepsis\n* Has undergone surgery in the past 6 months\n* Have high inflammatory diseases, malignancy, or cancer\n* Have dialysis adequacy of \\\u003C1.2 Kt\u002FV",{"count":86,"type":21},100,[24],"The goal of this clinical trial is to determine whether a plant-focused diet improves nutritional and health outcomes of malnourished adults undergoing peritoneal dialysis (PD). It will also learn about the safety of this diet in this population.\n\nThe main questions it aims to answer are:\n\n1. Does a plant-focused diet improve nutritional status compared to a standard kidney diet in PD patients?\n2. What changes occur in anthropometric, biochemical, and dietary measures over 6 months?\n\nResearchers will compare the plant-focused diet to a standard-of-care renal diet to see which is more effective in improving nutrition in PD patients.\n\nParticipants will:\n\n* Be randomly assigned to follow the plant-focused diet or the standard diet.\n* Be monitored for 6 months through in-person visits (aligned with their routine clinic appointments) and virtual check-ins via messages or calls.\n* Have their progress monitored for changes in outcomes such as nutrition, blood tests, kidney function, and quality of life.",[90,62,27,91],"End Stage Renal Disease (ESRD)","Malnourished",[93,94,95,96,97,98,99,100,101,102,103,104,105,106],"Peritoneal Dialysis","End Stage Renal Disease","End Stage Kidney Disease","Malnutrition","Plant-Focused Diet","Plant-Based Diet","Nutritonal Status","Dietary Counselling","Quality of Life","Physical Fitness","Inflammation","Appetite","Malaysia","Nutritional Intervention","2026-03-12",{"date":109,"type":38},"2026-03-16",{"date":111,"type":38},"2026-03-10",{"date":113,"type":21},"2027-03-31",{"name":115,"class":45},"National University of Malaysia",1,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":125,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":128,"conditions":129,"keywords":133,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100626595","a-survey-for-patients-and-caregivers-aiming-to-understand-and-improve-the-care-of-patients-at-high-risk-of-transfer-from-peritoneal-dialysis-to-hemodialysis-100626595","NCT07437677","A Survey for Patients and Caregivers Aiming to Understand and Improve the Care of Patients at High Risk of Transfer From Peritoneal Dialysis to Hemodialysis:","Understand, Plan and Improve Care and Wellbeing of Patients at High Risk of Transfer From Peritoneal Dialysis to Hemodialysis - Phase 2 (Survey)","ULIFT-PD","Inclusion Criteria:\n\n1. Adult (≥18 years)\n2. One of the following:\n\n   * Patient who experienced a PD-to-HD transition in past 12 months\n   * Patient currently receiving peritoneal dialysis\n   * Caregiver (self-defined, including spouses, family members, or friends) of individuals meeting the above criteria\n3. Able to read English or French\n4. Able to complete the survey in paper or web-based format\n5. Able to provide informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Unable to provide consent",true,{"count":127,"type":21},200,"Home dialysis is encouraged in Canada and peritoneal dialysis is the most common home dialysis method. However, many patients discontinue peritoneal dialysis, often transferring to hemodialysis. Despite the frequency of this transition, little is known about its impact on patients.\n\nOverall, the UPLIFT-PD program aims to fill this gap by studying the transition from peritoneal dialysis to hemodialysis. The specific goal of this mixed methods sub-study is to conduct a national survey to ask patients and caregivers about priorities and preferences when they anticipate a transfer from peritoneal dialysis to hemodialysis. This survey will be co-created by patient-partners and dialysis experts.\n\nResults from this survey will then be used in other phases of UPLIFT-PD program, detailed in other registrations, which will support people facing a transition from peritoneal dialysis to hemodialysis..",[27,130,131,132],"Hemodialysis","Kidney Replacement Therapy","Transition",[134],"Transfer to hemodialysis","NOT_YET_RECRUITING","2026-02-24",{"date":138,"type":38},"2026-02-27",{"date":140,"type":21},"2027-01",{"date":142,"type":21},"2029-12",{"name":144,"class":45},"Ciusss de L'Est de l'Île de Montréal",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":116},"100618012","pilot-study-to-evaluate-the-feasibility-adherence-and-acceptance-of-the-midilisis-platform-for-patients-on-pd-100618012","NCT07326085","Pilot Study to Evaluate the Feasibility, Adherence and Acceptance of the MiDiálisis Platform for Patients on PD","Pilot Study of MiDialisis App Usage (Estudio Piloto de Uso de MiDiálisis App)","PUMA","Inclusion Criteria:\n\n* Patients over 18 years of age.\n* Patients with chronic kidney disease who have been on PD for at least 3 months in the same hospital.\n* Patients with a stable clinical condition during the 3 months prior to entering the study, defined as no unscheduled hospitalizations or major cardiovascular events (myocardial infarction or stroke) during that period.\n* Availability of a smartphone or tablet and internet access for the patient\u002Fcaregiver.\n* Patients who understand the nature of the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients with limitations for multifrequency body composition measurement (pacemaker or implantable cardioverter defibrillator wearers, and pregnant women).\n* Patients who do not routinely use a smartphone or are unfamiliar with the use of mobile applications.\n* Patients who are scheduled for a living kidney transplant in the next 6 months.\n* Patients with a life expectancy of less than 6 months.\n* Patients in a peritoneal ultrafiltration program due to cardiorenal syndrome.",{"count":154,"type":21},55,[24],"The main goal of this study is to assess whether a mobile phone app called MiDiálisis is practical, easy to use, and well-accepted. The app was developed by the Technical University of Madrid (UPM) and is designed to bring together the clinical data of people with chronic kidney disease who are on peritoneal dialysis. This way, both patients and doctors can access the information at any time.",[27],[159,160],"peritoneal dialysys","remote monitoring","2026-01-03",{"date":163,"type":38},"2026-01-08",{"date":165,"type":38},"2025-07-27",{"date":167,"type":21},"2026-11-30",{"name":169,"class":45},"Aida Frías González",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":4},"100579949","phase-4-iron-isomaltoside-for-the-treatment-of-anemia-in-peritoneal-dialysis-patients-100579949","NCT06830941","Iron Isomaltoside for the Treatment of Anemia in Peritoneal Dialysis Patients","Efficacy and Safety of Iron Isomaltoside in the Treatment of Peritoneal Dialysis Patients with Renal Related Anemia: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Males or females who are ≥ 18 years and on PD treatment for ≥90 days, body weight≥50Kg\n2. Hemoglobin(Hb）≤110 g\u002FL at screening phase\n3. Serum ferritin(SF）≤200 μg\u002FL or transferrin saturation(TSAT）≤20% at screening phase\n4. No oral or intravenous iron use within 4 weeks prior to screening.\n5. No hypoxia-inducible factor prolyl hydroxylase inhibitor（HIF-PHI）used or other erythropoiesis-stimulating agent（ESA）except for erythropoietin (EPO) used in the past 4 weeks prior to screening\n6. Stable doses of erythropoiesis-stimulating agents (ESA) with a change of dose ≤20% during the past 4 weeks.\n7. Willing to participate and signed the informed consent form\n\nExclusion Criteria:\n\n1. Anemia predominantly caused by other diseases rather than renal diseases according to the investigator's judgement. (eg. bleeding, hematological diseases, anemia due to autoimmune diseases)\n2. History of disturbances in iron utilisation.(eg. hemochromatosis and hemosiderosis）\n3. Anemia due to lack of folate or vitamin B12：folate\\\u003C6.8nmol\u002FL（3ng\u002Fml）and(or) Vitamin B12\\\u003C74pmol\u002FL（100pg\u002Fml）at screening phase\n4. Histories of serious allergies to iron\n5. Obvious liver dysfunction：ALT\\>3×ULN and\u002For AST\\>3×ULN，or total bilirubin\\>1.5×ULN\n6. Active acute or chronic infection(clinically diagnosed)\n7. Uncontrolled secondary hyperparathyroidism：PTH or iPTH\\>9×ULN；\n8. History of malignancy within 5 years\n9. Acute coronary syndrome, strokes (except for lacunar cerebral infarction), serious thromboembolism (eg. DVT or PE) within 6 months before the screening period\n10. NYHA grade III or IV of congestive heart failure or severe arrythmia(including ventricular tachycardia, ventricular fibrillation, AV-block III etc.) within 6 months before screening\n11. Pregnant or during lactation period or not willing to get contraception\n12. Planning to receive renal transplantation within 2 months\n13. Accepted blood transfusion within 3 months.\n14. Serum ferritin，SF\\>500 μg\u002FL\n15. Planning to recieve the treatment as operations, chemotherapies or radiotherapies etc. during the research period\n16. Other situations not suitable for inclusion decided by researchers. Rescreening is allowed if it failed in the first time of screening.",{"count":178,"type":21},124,[180],"PHASE4","This is a prospective multicenter randomized controlled clinical study. The goal of this clinical trial is to learn if intravenous iron isomaltoside injection use is equally effective and safe for the treatment of renal anemia in peritoneal dialysis patients compared with oral ferrous succinate tablets.\n\nThe main questions to answer are:\n\n* Changes in hemoglobin concentration from baseline to week 8 after the use of single dose intravenous iron isomaltoside injection in peritoneal dialysis patients with renal anemia.\n* If intravenous iron isomaltoside injection use is equally effective and safe for the treatment of renal anemia in peritoneal dialysis patients compared with oral ferrous succinate tablets.\n\nParticipants will:\n\n* be randomized 1:1 to two groups, either Iron isomaltoside Group (Group A, experimental group) or Ferrous succinate Group (Group B, control group).\n* Patients in Iron isomaltoside Group will receive a single dose of intravenous iron isomaltoside injection, the dose of which is set at 1000 mg. Patients in Ferrous succinate Group will receive ferrous succinate treatment orally given as 200mg twice a day for 8 weeks (containing iron element 7840mg in total).\n* Patients will be followed up for 8 weeks.",[183,27],"Renal Anemia",[32,185,186,187],"renal anemia","iron isomaltoside","iron treatment","2025-02-13",{"date":190,"type":38},"2025-02-17",{"date":192,"type":21},"2025-02-15",{"date":194,"type":21},"2027-12-31",{"name":196,"class":45},"Xie Jingyuan, MD"]